Hypnotic medication use among inpatients with schizophrenia and major depressive disorder: results of a nationwide study.


Journal

Sleep medicine
ISSN: 1878-5506
Titre abrégé: Sleep Med
Pays: Netherlands
ID NLM: 100898759

Informations de publication

Date de publication:
01 2022
Historique:
received: 02 08 2021
revised: 09 11 2021
accepted: 11 11 2021
pubmed: 8 12 2021
medline: 2 4 2022
entrez: 7 12 2021
Statut: ppublish

Résumé

To investigate the proportion of inpatients with schizophrenia and major depressive disorder prescribed hypnotic medication, and the association between such medication and the use of other antipsychotic agents. This was a nationwide cross-sectional study performed as part of the 'Effectiveness of Guidelines for Dissemination and Education in Psychiatric Treatment' (EGUIDE) project. Data from 2146 inpatients with schizophrenia and 1031 inpatients with major depressive disorder were analyzed. All types and dosages of psychotropic drugs were recorded and the data at the time of discharge were analyzed. Associations between the use of hypnotic medication and other antipsychotic agents were evaluated using multivariate logistic regression analyses. The proportions of schizophrenia patients who were prescribed any and two or more hypnotic agents were 55.7% and 17.6%, respectively, and the corresponding proportions for patients with major depressive disorder were 63.6% and 22.6%, respectively. In schizophrenia patients, multivariate logistic regression analyses showed that two or more antipsychotics, anticholinergic drugs, anxiolytics, and mood stabilizers/antiepileptic drugs were positively associated with the use of any hypnotic agent. In patients with major depressive disorder, multivariate logistic regression analyses revealed that two or more antidepressants, two or more antipsychotics, anxiolytics, and mood stabilizers/antiepileptic drugs were positively associated with the use of any hypnotic agent. Prescription of hypnotic agents was found to be highly frequent among inpatients with psychiatric disorders. Prescription of two or more main antipsychotic agents was commonly associated with the use of hypnotic medication for both schizophrenia and major depressive disorder.

Identifiants

pubmed: 34875519
pii: S1389-9457(21)00554-2
doi: 10.1016/j.sleep.2021.11.005
pii:
doi:

Substances chimiques

Antipsychotic Agents 0
Hypnotics and Sedatives 0

Types de publication

Journal Article Research Support, Non-U.S. Gov't

Langues

eng

Sous-ensembles de citation

IM

Pagination

23-30

Informations de copyright

Copyright © 2021 Elsevier B.V. All rights reserved.

Auteurs

Ryuji Furihata (R)

Kyoto University Health Service, Japan.

Rei Otsuki (R)

Department of Psychiatry, Nihon University School of Medicine, Japan.

Naomi Hasegawa (N)

Department of Pathology of Mental Diseases, National Institute of Mental Health, National Center of Neurology and Psychiatry, Japan.

Takashi Tsuboi (T)

Department of Neuropsychiatry, Kyorin University School of Medicine, Japan.

Shusuke Numata (S)

Department of Psychiatry, Graduate School of Biomedical Science, Tokushima University, Japan.

Norio Yasui-Furukori (N)

Department of Psychiatry, Dokkyo Medical University School of Medicine, Japan.

Hiroko Kashiwagi (H)

Department of Pathology of Mental Diseases, National Institute of Mental Health, National Center of Neurology and Psychiatry, Japan; Department of Forensic Psychiatry, National Center Hospital, National Center of Neurology and Psychiatry, Japan.

Hikaru Hori (H)

Department of Psychiatry, Faculty of Medicine, Fukuoka University, Japan.

Shinichiro Ochi (S)

Department of Neuropsychiatry, Molecules and Function, Ehime University Graduate School of Medicine, Japan.

Hiroyuki Muraoka (H)

Department of Psychiatry, Tokyo Women's Medical University, Japan.

Toshiaki Onitsuka (T)

Department of Neuroimaging Psychiatry, Graduate School of Medical Sciences, Kyushu University, Japan.

Hiroshi Komatsu (H)

Department of Psychiatry, Tohoku University Hospital, Japan.

Masahiro Takeshima (M)

Department of Neuropsychiatry, Akita University Graduate School of Medicine, Japan.

Akitoyo Hishimoto (A)

Department of Psychiatry, Yokohama City University Graduate School of Medicine, Japan.

Tatsuya Nagasawa (T)

Department of Neuropsychiatry Kanazawa Medical University, Japan.

Yoshikazu Takaesu (Y)

Department of Neuropsychiatry, Graduate School of Medicine, University of the Ryukyus, Japan.

Toshinori Nakamura (T)

Department of Psychiatry, Shinshu University School of Medicine, Japan.

Takeshi Asami (T)

Department of Psychiatry, Yokohama City University Graduate School of Medicine, Japan.

Kenichiro Miura (K)

Department of Pathology of Mental Diseases, National Institute of Mental Health, National Center of Neurology and Psychiatry, Japan.

Junya Matsumoto (J)

Department of Pathology of Mental Diseases, National Institute of Mental Health, National Center of Neurology and Psychiatry, Japan.

Kazutaka Ohi (K)

Department of Psychiatry, Gifu University Graduate School of Medicine, Japan.

Yuka Yasuda (Y)

Department of Pathology of Mental Diseases, National Institute of Mental Health, National Center of Neurology and Psychiatry, Japan; Medical Corporation Foster, Japan.

Hitoshi Iida (H)

Department of Psychiatry, Faculty of Medicine, Fukuoka University, Japan.

Kazuyoshi Ogasawara (K)

Center for Postgraduate Clinical Training and Career Development, Nagoya University Hospital, Japan.

Naoki Hashimoto (N)

Department of Psychiatry, Hokkaido University Graduate School of Medicine, Japan.

Kayo Ichihashi (K)

Department of Neuropsychiatry, University of Tokyo Hospital, Japan.

Hisashi Yamada (H)

Department of Neuropsychiatry, Hyogo College of Medicine, Japan; Department of Pathology of Mental Diseases, National Institute of Mental Health, National Center of Neurology and Psychiatry, Japan.

Koichiro Watanabe (K)

Department of Neuropsychiatry, Kyorin University School of Medicine, Japan.

Ken Inada (K)

Department of Psychiatry, Tokyo Women's Medical University, Japan.

Ryota Hashimoto (R)

Department of Pathology of Mental Diseases, National Institute of Mental Health, National Center of Neurology and Psychiatry, Japan. Electronic address: ryotahashimoto55@ncnp.go.jp.

Articles similaires

[Redispensing of expensive oral anticancer medicines: a practical application].

Lisanne N van Merendonk, Kübra Akgöl, Bastiaan Nuijen
1.00
Humans Antineoplastic Agents Administration, Oral Drug Costs Counterfeit Drugs

Smoking Cessation and Incident Cardiovascular Disease.

Jun Hwan Cho, Seung Yong Shin, Hoseob Kim et al.
1.00
Humans Male Smoking Cessation Cardiovascular Diseases Female
Humans United States Aged Cross-Sectional Studies Medicare Part C
1.00
Humans Yoga Low Back Pain Female Male

Classifications MeSH